businesswire.com · Oct 8, 2025
Navidea Biopharmaceuticals, Inc. Files for Bankruptcy
COLUMBUS, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (“Navidea” or the “Company”), a biopharmaceutical company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that it filed a voluntary petition for relief under Chapter 11, Subchapter V of the United States Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware (the “Court”) on October 1, 2025. The filing is intended to enable the Company to pursue an orderly.
